A novel antifolate, MX-68, inhibits the development of autoimmune disease in mrl/lpr mice

International Archives of Allergy and Immunology

Volumn 113, Issue 4, 1997, Pages 454-459

  Mihara, Masahiko ^a   Takagi, Nobuyuki ^a   Urakawa, Kazumi ^a   Moriya, Yoichiro ^a   Takeda, Yasuhisa ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Autoantibody; Lupus nephritis; Methotrexate; MRL lpr mice; MX 68

Indexed keywords

AUTOANTIBODY; CHOLESTEROL; FOLIC ACID ANTAGONIST; METHOTREXATE; N [[4 [(2,4 DIAMINO 6 PTERIDINYL)METHYL] 3,4 DIHYDRO 2H 1,4 BENZOTHIAZIN 7 YL]CARBONYL]HOMOGLUTAMIC ACID; N [[4 [(2,4 DIAMINOPTERIDIN 6 YL)METHYL] 3,4 DIHYDRO 2H 1,4 BENZOTHIAZIN 7 YL]CARBONYL]HOMOGLUTAMIC ACID; POLYGLUTAMIC ACID; PTEROPTIN; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; DRUG THERAPY; FEMALE; KIDNEY DISEASE; LIFESPAN; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPH NODE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PREVENTION; PRIORITY JOURNAL; PROTEINURIA; SPLEEN; UREA NITROGEN BLOOD LEVEL;

EID: 0030740758     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000237622     Document Type: Article

References (26)

1. Wcinblatt ME, C'oblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trcntham DE: Efficacy of low-dose mctholrcxatc in rheumatoid arthritis. N Engl J Med 1985:312:818-822.
2. Weinstein GD, Frost P: Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 1971:103:33-38.
3. Owen ET, Cohen ML: Methotrexate in Reiter's disease. Ann Rheum Dis 1979:38:48-50.
4. Arnett FC, Whelton JC, Zizic TM, Stevens MB: Methotrexate therapy in polymyositis. Ann Rheum Dis 1973:32:536-546.
5. Lower EE, Baughman RP: The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sei 1990:229:153-157.
6. Rothenberg RI, Graziano FM, Grandonc JT, Goldberg JW, Bjarnason DF, Finesilver AG: The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis Rheum 1988;31:612-615.
7. Shiner R, Nunn AJ, Fan Chung K, Geddcs DM: Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 1988:336:137-140.
8. Mihara M, Urakawa K, Takagi N, Moriya Y, Takeda Y: In vitro and in vivo biological activities of a novel nonpolyglutamable anti-folate, MX-68. Immunopharmacology 1996:35:41-46.
9. Murphy ED, Roths JB: Autoimmunity and lym-phoproliferation: Induction by mutant gene Ipr and acceleration by a male-associated factor in strain BxSB mice: in Rose NR. Bigazzi PE. Waincr NL (eds): Genetic Control of Autoimmune Disease. New York. Elsevier-North Holland. 1979. pp 207-220.
10. Andrews BS, Eisenberg RS, Theofilopoulos AN, Izui S, Wilson CB, McConahey PJ, Murphy ED, Roths JB, Dixon FJ: Spontaneous murine lupus-like syndromes; Clinical and im-munopathological manifestations in several strains. J Exp Med 1978:148:1198-1215.
11. Yamane N, Sakamoto F, Matsuura F: Quantification of urinary glucose and protein with test strips through rellcctomctric analysis. Clin Bio-chem 1988:21:271-275.
12. Mihara M, Nakano T, Ohsugi Y: An immuno-modulating anti-rheumatic drug, lobenzarit disodium (CCA): Inhibition of polyclonal B-ccll activation and prevention of autoimmune disease in MRL/Mp-lpr/lpr mice. Clin Immunol Immunopathol I987;45:366 374.
13. Mihara M, Katsume A, Takeda T: Effect of methotrexate treatment on the onset of autoimmune kidney disease in lupus mice. Client Pharm Bull (Tokyo) 1992:40:2177-2181.
14. Baggott JE, Morgan SL, Frecberg LE, Hudson BB, Vaughn WFI, Gopal Nair M, Krumdieck CL, Koopman WJ, Gay RE, Gay S: Long-term treatment of the MRI./lpr mouse with methotrexate and 10-deazaaminoptcrin. Agents Actions 1992:35:104-111.
15. Segal R, Dayan M, Zinger H, Mozcs E: Methotrexate treatment in murine experimental systemic lupus erythematosus: Clinical benefits associated with cytokine manipulation. Clin Immunol Immunopathol 1995:101:366-374.
16. Yamamoto K, Mori A, Nakahama T, Ito M, Okudaira II, Miyamoto T: Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK 506. Immunology 1990:69:222-227.
17. Shiraki M, Fujiwara M, Tomura S: Long-term administration of cyclophosphamide in MRL I mice. I. The effects on the development of immunological abnormalities and lupus nephritis. Clin Exp Immunol 1984:55:333-339.
18. Ito S, Ueno M, Arakawa M, Saito T, Aoyagi T, Fujiwara M: Therapeutic effect of 15-deoxys-pcrgualin on the progression of lupus nephritis in MRL mice. I. lmmunopathological analyses. Clin Exp Immunol 1990:81:446-453.
19. Mansour A, Nelson DS: Effect of hydrocortisone. cyclophosphamide, azathioprine and methotrexate on cutaneous delayed and Arthus hypersensitivity in the rat. Int Arch Allergy Appl Immunol 1979:60:50-59.
20. O'Meara AMW, Brazil J, Recn DJ: The effect of methotrexate on in vitro immunoglobulin production. J Immunopharmacol 1985;7:235-245.
21. Sperling RI, Benincaso AI, Anderson RJ, Co-blyn JS, Frank Austen K, Wcinblatt ME: Acute and chronic suppression of leukotriene B, ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum 1992;35:376-384.
22. Spurncy RF, Ruiz P, Pisetsky DS, Coffman TM: Enhanced renal leukotriene production in murine lupus: Role of lipoxygenase metabolites. Kidney Int 1991:39:95-102.
23. Izui S, Fernandes G, Hara I, McConahey PJ, Jensen FC, Dixon FJ, Good RA: Low-calorie diet selectively reduces expression of retroviral envelope glycoprotein gp70 in sera of NZBxNZW F, hybrid mice. J Exp Med 1981; 154:1116-1124.
24. Baugh CM, Kurumdieck CL, Nair MG: Poly-gammaglutamyl metabolites of methotrexate. Biocliem Biophys Res Commun 1973:52:27-34.
25. Allcgra CI, Drake JC, Jolivet J, Chabncr BA: Inhibition of folate-dependent enzymes by methotrexate polyglutamates; in Goldman ID (cd): Proceedings of the Second Workshop on Foly and Antifolyl Polyglutamates. Oxford, Pergamon Press. 1984, pp 348-359.
26. Baggott JE, Vaughn WH, Hudson BB: Inhibition cf 5-aminoimidazole-4-carboxamidc ri bolide transformylasc. adenosine deaminase, and 5’-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5'-aminoimidazole-4-carboxamide riboside and ribotide. Biocliem J 1986:236:193-200.